GAS6 and Alzheimer disease: As evidenced by an Aß-specific-growth arrest-specific 6 (Aß-Gas6) monoclonal antibody, which can induce microglial Aβ clearance without triggering inflammatory responses or reactive gliosis in preclinical models, future strategies should also consider how the application of multiple compounds with complementary immune effects (e.g., anti-inflammation, phagocytosis) might boost resiliency to AD [171].